We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
+12.81%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$225M
AUM Growth
-$5.82M
(-2.5%)
Cap. Flow
-$29.2M
Cap. Flow
% of AUM
-12.97%
Top 10 Holdings %
Top 10 Hldgs %
45.19%
Holding
92
New
27
Increased
21
Reduced
24
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sanofi
SNY
|
+$5.69M |
| 2 |
WMGI
Wright Medical Group Inc
WMGI
|
+$5.36M |
| 3 |
TVTY
Tivity Health, Inc. Common Stock
TVTY
|
+$5.15M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$4.63M |
| 5 |
RCM
R1 RCM Inc. Common Stock
RCM
|
+$4.26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$11.9M |
| 2 |
Abbott
ABT
|
+$11.6M |
| 3 |
Johnson & Johnson
JNJ
|
+$7.46M |
| 4 |
Universal Health Services
UHS
|
+$7.16M |
| 5 |
AGN
Allergan plc
AGN
|
+$6.71M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.74% |
| 2 | Industrials | 2.11% |
| 3 | Financials | 2.08% |
| 4 | Technology | 0.89% |
| 5 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Cigna
CI
$73.7B
| $17.2M | 7.67% |
82,814
+18,353
| +28% | +$3.4M |
|
|
SHPG
2
DELISTED
Shire pic
SHPG
| $16.3M | 7.27% |
90,143
+22,250
| +33% | +$3.85M |
|
|
AGN
3
DELISTED
Allergan plc
AGN
| $15M | 6.65% |
78,520
-36,552
| -32% | -$6.71M |
|
|
TVTY
4
DELISTED
Tivity Health, Inc. Common Stock
TVTY
| $9.99M | 4.44% |
310,596
+150,904
| +94% | +$5.15M |
|
|
WMGI
5
DELISTED
Wright Medical Group Inc
WMGI
| $8.91M | 3.97% |
307,216
+198,958
| +184% | +$5.36M |
|
|
CELG
6
DELISTED
Celgene Corp
CELG
| $8.81M | 3.92% |
98,401
+27,196
| +38% | +$2.4M |
|
7
CVS Health
CVS
$133B
| $7.2M | 3.2% |
91,418
-15,655
| -15% | -$1.12M |
|
8
Medtronic
MDT
$109B
| $6.41M | 2.85% |
65,129
-59,595
| -48% | -$5.51M |
|
|
9
Sanofi
SNY
$103B
| $5.95M | 2.65% |
+133,245
| New | +$5.69M |
|
|
10
Abbott
ABT
$183B
| $5.78M | 2.57% |
78,718
-177,089
| -69% | -$11.6M |
|
|
11
Merck
MRK
$322B
| $5.68M | 2.53% |
83,937
-186,524
| -69% | -$11.9M |
|
12
Baxter International
BAX
$13.5B
| $5.26M | 2.34% |
68,190
-12,039
| -15% | -$893K |
|
13
Zimmer Biomet
ZBH
$18.2B
| $5.2M | 2.31% |
40,751
+17,620
| +76% | +$2.1M |
|
14
DaVita
DVA
$15.4B
| $5.02M | 2.23% |
70,090
-68,586
| -49% | -$4.85M |
|
|
15
Bristol-Myers Squibb
BMY
$133B
| $4.84M | 2.15% |
+77,971
| New | +$4.63M |
|
|
OXFD
16
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $4.79M | 2.13% |
295,229
+138,360
| +88% | +$1.98M |
|
17
Stryker
SYK
$125B
| $4.77M | 2.12% |
26,821
+17,461
| +187% | +$2.98M |
|
|
RCM
18
DELISTED
R1 RCM Inc. Common Stock
RCM
| $4.75M | 2.11% |
+467,463
| New | +$4.26M |
|
|
AET
19
DELISTED
Aetna Inc
AET
| $4.67M | 2.08% |
23,017
-6,180
| -21% | -$1.21M |
|
20
Elevance Health
ELV
$81.5B
| $4.66M | 2.07% |
17,008
-19,928
| -54% | -$5.17M |
|
21
Bausch Health
BHC
$2.58B
| $4.22M | 1.88% |
164,441
+117,512
| +250% | +$2.69M |
|
22
Standard BioTools
LAB
$340M
| $4.21M | 1.87% |
562,584
+448,474
| +393% | +$3.19M |
|
23
Pfizer
PFE
$143B
| $4.07M | 1.81% |
97,379
+61,383
| +171% | +$2.36M |
|
24
Viatris
VTRS
$20.4B
| $3.94M | 1.75% |
107,778
-71,497
| -40% | -$2.68M |
|
|
HOLX
25
DELISTED
Hologic
HOLX
| $3.81M | 1.7% |
93,045
+9,389
| +11% | +$380K |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q3 2018 Portfolio in Review
As of Q3 2018, Endurant Capital Management held 92 positions worth $225M, down 2.5% from $231M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Endurant Capital Management withdrew a net $29.2M in Q3 2018, closing 19 positions and reducing 24 holdings. Its most notable exit was Universal Health Services, an estimated $7.16M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Industrials and Financials.
Against the trend, Endurant Capital Management opened a new position in Sanofi worth $5.95M.
- Endurant Capital Management's largest Q3 2018 buy was Sanofi: 133,245 shares worth $5.95M.
- Endurant Capital Management added most to Wright Medical Group Inc in Q3 2018, an estimated $5.36M increase.
- Endurant Capital Management's biggest Q3 2018 reduction was Merck, cutting an estimated $11.9M.
- Endurant Capital Management fully exited Universal Health Services in Q3 2018, selling an estimated $7.16M.
- Endurant Capital Management's ten largest holdings make up 45% of its $225M portfolio in Q3 2018.
- Endurant Capital Management opened 27 new positions and closed 19 in Q3 2018.
- Endurant Capital Management's portfolio value fell 2.5% quarter-over-quarter to $225M.
Based on Endurant Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.